公开(公告)号：US20090306045A1

公开(公告)日：2009-12-10

申请号：US11991654

申请日：2006-12-22

申请人： Ira Mellman ,  Aimin Jiang

发明人： Ira Mellman ,  Aimin Jiang

IPC分类号： A61K31/55 ,  A61K31/4015 ,  A61P37/00

CPC分类号： A61K31/4745 ,  A61K31/503

摘要： The present invention relates to the use of glycogen synthase kinase 3(GSK3) inhibitors, especially inhibitors of GSK-3α, GSK-3β and GSK-3β2, preferably, inhibitors of GSK-3β, in patients having autoimmune diseases and/or immune dysfunction/dysregulation to induce immune tolerance. Inhibition of GSK leads to activation of a pathway of dendritic cell maturation which leads to a dendritic phenotype which attenuates, rather than induces, immune responses. The immune responses and mature dendritic cells produced by the method of the present invention redirect or attenuate the immune response in individuals, thus leading to effective therapies for a number of autoimmune diseases and/or diseases of immune dysfunction/dysregulation (immune inflammatory diseases), including systemic lupus erythematosus (SLE), autoimmune diabetes (type I diabetes mellitus), asthma, rheumatoid arthritis, inflammatory bowel disease, among numerous others.

摘要翻译： 本发明涉及在具有自身免疫性疾病和/或免疫功能障碍的患者中使用糖原合酶激酶3（GSK3）抑制剂，特别是GSK-3α，GSK-3β和GSK-3β2抑制剂，优选GSK-3β抑制剂 /失调诱导免疫耐受。 GSK的抑制导致树突细胞成熟途径的激活，这导致树突状表型减弱而不是诱导免疫应答。 通过本发明的方法产生的免疫应答和成熟树突状细胞改变或减弱个体的免疫应答，从而导致许多自身免疫疾病和/或免疫功能障碍/失调（免疫炎性疾病）疾病的有效治疗， 包括系统性红斑狼疮（SLE），自身免疫性糖尿病（I型糖尿病），哮喘，类风湿性关节炎，炎性肠病等。